$VKTX

Viking Therapeutics (VKTX) is developing a monthly weight-loss injection, VK2735, aiming to compete with Big Pharma. CEO Brian Lian highlights tolerability as a key factor, with results expected this quarter. The stock fell 1% on Monday. Viking plans to test the drug in a 52-week extension study and start Phase 3 trials for an oral version. VKTX has risen 27% over the past year.

Viking Therapeutics (VKTX) is advancing its obesity drug VK2735 into Phase 3 trials after achieving 15% weight loss in Phase 2. The Phase 3 studies will test various dosing schedules and formulations, with a focus on tolerability and weight-loss maintenance. The company aims to leverage data from injectable studies for its oral program, reducing enrollment by about 75%. Viking is also preparing for commercialization, securing manufacturing capacity and supply-chain redundancy.

CRISPR Therapeutics (CRSP) and Viking Therapeutics (VKTX) are highlighted as potential pharmaceutical stocks to buy. CRISPR's Casgevy treatment is expected to generate significant revenue in 2027, with analysts projecting revenue to grow from $40M to $156M. Viking Therapeutics is developing a monthly GLP-1 weight-loss injection and an oral pill, with analysts setting a 12-month price target of $93.11 for VKTX, a 175% increase from its current price.

Axsome Therapeutics (AXSM) and Viking Therapeutics (VKTX) are compared as potential healthcare stock investments. Axsome, with products like Auvelity and Sunosi, reported $638.5M revenue in FY 2025, up 65.5%, but a net loss of $183.2M. Viking, in clinical trials, has no revenue but focuses on obesity treatments. Axsome has significant debt, while Viking has no debt but high research costs. Both face risks, with Axsome's reliance on few products and Viking's clinical trial uncertainties.

U.S. stock futures mostly rose late Wednesday as traders reacted to a strong January jobs report and a House vote to rescind Trump's Canadian tariffs. VKTX shares jumped 9% after announcing late-stage obesity drug trials. CRM hit a 52-week low amid AI concerns. NVCR surged 30% after FDA approval for a pancreatic cancer treatment. QS rose 10% despite reporting a quarterly loss. Retail investors increased purchases of software stocks, with IGV seeing record activity. The 10-year Treasury yield ros

Eli Lilly (LLY) and Novo Nordisk (NVO) led gains in obesity-drug stocks in May. Viking Therapeutics (VKTX) received a 'Buy' rating and $83 price target from Truist, citing its obesity pipeline and 162% upside potential. LLY raised its 2026 sales outlook after Q1 revenue rose 56% to $19.8B. NVO defended its obesity strategy, focusing on broader health outcomes and oral drug advantages.

Viking Therapeutics (VKTX) shares rose 2.3% since its last earnings report, underperforming the S&P 500. The company reported a narrower Q2 2026 loss of $1.10 per share, beating estimates but widening from the prior year. R&D costs surged 92.4% due to clinical studies and other expenses. The company has $502M in cash, enough to fund operations into 2028. Analysts have revised estimates upward by 8.26% since the report.

Raymond James reiterated a 'Strong Buy' rating and $118 price target for Viking Therapeutics (VKTX), implying 258% upside. Consensus expects a GAAP loss of $1.03 per share, wider than last year. Investors focus on the Phase 3 Vanquish obesity program, with a maintenance-dose study expected in Q3. VKTX shares outperformed peers like LLY and ALT over the past month.

Wolfpack Research reported Flotek Industries (FTK) lost a $400M contract, potentially halving its backlog. Fugazi Research criticized Aeva Technologies (AEVA) as a struggling startup. Bristlemoon Research argued Macy's (M) is overvalued. L3Harris (LHX) CEO departed over conduct violations. Ameresco (AMRC) CFO and GC resigned. Viking Therapeutics (VKTX) COO and Merit Medical (MMSI) COO departed. Boston Beer (SAM) CFO is stepping down. Edwin Dorsey predicts long-term trouble for DraftKings (DKNG)

Viking Therapeutics (VKTX) shares rose 7% after the company initiated a human trial for its obesity drug VK3019. The study will assess safety, tolerability, and weight effects. VK3019 targets amylin and calcitonin receptors, potentially offering a new weight management option. Raymond James maintains a 'Strong Buy' rating, citing pipeline expansion and near-term catalysts. Analysts' average price target is $92.58, implying 166% upside.